UCB : The recovery continues
>H1 reassures that UCB will meet the upper end of its 2024 guidance range - UCB released a very solid set of H1 results yesterday while we were expecting them to reach a trough (-12% cc) due to the comparison base and the launch of Bimzelx. Bimzelx delivered the pleasant surprise of this release. Indication extensions in Europe and improvements to reimbursement policies in the USA pushed sales of the drug higher than we had expected. The drug is indeed enjoying excel...UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.